Tollys extends its executive management team
with appointment of Bettina Werle as CSO

Bettina Werle will supervise the laboratory, help set its scientific priorities and lead Tollys’ R&D team

Tollys, the developer of TL-532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, today announces the appointment of Bettina Werle as chief scientific officer (CSO). Bettina will be responsible for all research and scientific activities at Tollys. Her appointment comes at a time when Tollys is starting its regulatory toxicology studies with a view to entering phase 1 clinical trials in 2022.